Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -79.56 Billion KRW | 19.04% |
| 2022 | -98.26 Billion KRW | -20.29% |
| 2021 | -81.68 Billion KRW | -1003.02% |
| 2020 | -7.4 Billion KRW | -8.66% |
| 2019 | -6.81 Billion KRW | -910.44% |
| 2018 | -674.5 Million KRW | -152.24% |
| 2017 | 1.29 Billion KRW | 136.78% |
| 2016 | -3.51 Billion KRW | -114.8% |
| 2015 | 23.72 Billion KRW | 64.06% |
| 2014 | 14.46 Billion KRW | -39.24% |
| 2013 | 23.8 Billion KRW | 70.33% |
| 2012 | 13.97 Billion KRW | -63.88% |
| 2011 | 38.69 Billion KRW | 38.23% |
| 2010 | 27.99 Billion KRW | -21.31% |
| 2009 | 35.57 Billion KRW | 33.99% |
| 2008 | 26.54 Billion KRW | -45.37% |
| 2007 | 48.6 Billion KRW | -1.68% |
| 2006 | 49.43 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 490 Million KRW | 112.84% |
| 2024 Q1 | -3.81 Billion KRW | 56.36% |
| 2024 Q3 | 105 Million KRW | -78.57% |
| 2023 Q3 | -23.53 Billion KRW | 9.83% |
| 2023 Q2 | -26.09 Billion KRW | -23.28% |
| 2023 Q1 | -21.17 Billion KRW | 27.43% |
| 2023 Q4 | -8.74 Billion KRW | 62.84% |
| 2023 FY | -79.55 Billion KRW | 19.04% |
| 2022 FY | -98.26 Billion KRW | -20.29% |
| 2022 Q1 | -15.44 Billion KRW | 42.49% |
| 2022 Q2 | -28.57 Billion KRW | -85.0% |
| 2022 Q3 | -25.07 Billion KRW | 12.23% |
| 2022 Q4 | -29.17 Billion KRW | -16.33% |
| 2021 Q3 | -19.81 Billion KRW | -35.4% |
| 2021 Q4 | -26.85 Billion KRW | -35.53% |
| 2021 Q1 | -21.53 Billion KRW | -134.07% |
| 2021 Q2 | -14.63 Billion KRW | 32.06% |
| 2021 FY | -81.68 Billion KRW | -1003.02% |
| 2020 Q4 | -9.2 Billion KRW | -47.56% |
| 2020 FY | -7.4 Billion KRW | -8.66% |
| 2020 Q1 | -3.67 Billion KRW | 80.01% |
| 2020 Q2 | 9.89 Billion KRW | 369.4% |
| 2020 Q3 | -6.23 Billion KRW | -163.01% |
| 2019 Q3 | -10.39 Billion KRW | -528.42% |
| 2019 FY | -6.81 Billion KRW | -910.44% |
| 2019 Q2 | 2.42 Billion KRW | -4.87% |
| 2019 Q4 | -18.37 Billion KRW | -76.82% |
| 2019 Q1 | 2.55 Billion KRW | 205.79% |
| 2018 Q3 | 869.55 Million KRW | 406.16% |
| 2018 Q1 | 694.9 Million KRW | 74.6% |
| 2018 FY | -674.5 Million KRW | -152.24% |
| 2018 Q4 | -2.41 Billion KRW | -377.24% |
| 2018 Q2 | 171.79 Million KRW | -75.28% |
| 2017 Q3 | 968.73 Million KRW | 221.99% |
| 2017 Q2 | -794.09 Million KRW | -210.51% |
| 2017 Q1 | 718.53 Million KRW | 131.91% |
| 2017 FY | 1.29 Billion KRW | 136.78% |
| 2017 Q4 | 397.99 Million KRW | -58.92% |
| 2016 Q4 | -2.25 Billion KRW | -55.94% |
| 2016 FY | -3.51 Billion KRW | -114.8% |
| 2016 Q3 | -1.44 Billion KRW | -279.18% |
| 2016 Q2 | 805.84 Million KRW | -90.89% |
| 2016 Q1 | 8.84 Billion KRW | 1014.12% |
| 2015 FY | 23.72 Billion KRW | 64.06% |
| 2015 Q1 | 12.31 Billion KRW | 286.06% |
| 2015 Q2 | 4.65 Billion KRW | -62.17% |
| 2015 Q3 | 5.96 Billion KRW | 27.96% |
| 2015 Q4 | 793.66 Million KRW | -86.69% |
| 2014 Q4 | 3.18 Billion KRW | -32.3% |
| 2014 Q3 | 4.71 Billion KRW | 31.2% |
| 2014 Q2 | 3.59 Billion KRW | 20.87% |
| 2014 Q1 | 2.97 Billion KRW | -57.14% |
| 2014 FY | 14.46 Billion KRW | -39.24% |
| 2013 FY | 23.8 Billion KRW | 70.33% |
| 2013 Q4 | 6.93 Billion KRW | -33.02% |
| 2013 Q1 | 5.2 Billion KRW | -25.44% |
| 2013 Q3 | 10.34 Billion KRW | 682.91% |
| 2013 Q2 | 1.32 Billion KRW | -74.6% |
| 2012 FY | 13.97 Billion KRW | -63.88% |
| 2012 Q4 | 6.97 Billion KRW | 219.77% |
| 2012 Q3 | 2.18 Billion KRW | -71.72% |
| 2012 Q2 | 7.71 Billion KRW | 270.72% |
| 2012 Q1 | -4.52 Billion KRW | 0.0% |
| 2011 FY | 38.69 Billion KRW | 38.23% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 4.42 Billion KRW | -64.71% |
| 2011 Q1 | 13.44 Billion KRW | 0.0% |
| 2011 Q2 | 12.53 Billion KRW | -6.78% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 27.99 Billion KRW | -21.31% |
| 2010 Q3 | 9.03 Billion KRW | 51.39% |
| 2010 Q2 | 5.96 Billion KRW | 0.0% |
| 2009 FY | 35.57 Billion KRW | 33.99% |
| 2009 Q2 | 5.88 Billion KRW | 0.0% |
| 2009 Q3 | 11.53 Billion KRW | 95.85% |
| 2009 Q4 | 14.38 Billion KRW | 24.75% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 6.04 Billion KRW | -39.76% |
| 2008 Q2 | 7.06 Billion KRW | 0.0% |
| 2008 Q3 | 10.02 Billion KRW | 41.9% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | 26.54 Billion KRW | -45.37% |
| 2007 Q3 | 10.38 Billion KRW | 36.25% |
| 2007 FY | 48.6 Billion KRW | -1.68% |
| 2007 Q4 | 8.01 Billion KRW | -22.85% |
| 2007 Q2 | 7.62 Billion KRW | 0.0% |
| 2006 FY | 49.43 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | 21925.426% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 203.486% |
| HANDOK Inc. | 12.57 Billion KRW | 732.505% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | -3899.802% |
| Yuhan Corporation | 74.56 Billion KRW | 206.705% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 811.742% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | -340.968% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 135.379% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | 2703.41% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 654.421% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | 13440.275% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | 8355.306% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 394.33% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 21925.426% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | -925.802% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | 2072.461% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | -13.74% |
| JW Holdings Corporation | 143.66 Billion KRW | 155.38% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | -48.943% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 132.264% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 179.321% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -67.879% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 1248.587% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 1329.508% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 1011.217% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | 21925.426% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 263.145% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 159.638% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 179.321% |
| Yuhan Corporation | 74.56 Billion KRW | 206.705% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 480.311% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | 2652.188% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 285.049% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 179.321% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 488.403% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 244.79% |
| CKD Bio Corp. | -20.15 Billion KRW | -294.798% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 346.835% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 414.448% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 344.617% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | -67.879% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 340.028% |
| Boryung Corporation | 68.26 Billion KRW | 216.545% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | -112.183% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 654.421% |
| JW Lifescience Corporation | 32.09 Billion KRW | 347.922% |